Palifosfamide

DB05668InvestigationalSmall molecule

Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.

Mechanism: After metabolic activation, palifosfamide alkylates or binds with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily due to cross-linking of strands of DNA and RNA, as well as inhibition of protein synthesis.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified), lymphoma (unspecified), and sarcoma.Curator reviewed
Formula / weight: C₄H₁₁Cl₂N₂O₂P · 221.022 g/mol (avg)
Also known as: Ifosfamide mustard · Ifosforamide mustard · Isophosphamide mustard · Isophosphoramide mustard
Code names: NSC-297900 · ZIO-201

Resolves to

Compound

UNII6A4U6NN813CAS31645-39-3ChEMBLCHEMBL889ChEBI80566KEGGC16559

Structure

InChIKeyBKCJZNIZRWYHBN-UHFFFAOYSA-NSMILESOP(=O)(NCCCl)NCCCl

Targets

P26358DNMT1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Palifosfamide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account